We narrowed to 70 results for: STO

#58376-AAV8

Ready-to-use AAV8 particles produced from pAAV/D377Y-mPCSK9 (#58376). In addition to the viral particles, you will also receive purified pAAV/D377Y-mPCSK9 plasmid DNA. hAAT-driven expression of mutant (D377Y) murine PCSK9. These AAV preparations are suitable purity for injection into animals.

Jacob Bentzon

Bjorklund et al Circ Res. 2014 May 23;114(11):1684-9. do

July 30, 2025

Academic Institutions and Nonprofits only

#185386-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_OT1.0 (#185386). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OT1.0 plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) sensor GRAB_OT1.0 in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only

#185386-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-GRAB_OT1.0 (#185386). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OT1.0 plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) sensor GRAB_OT1.0 in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only

#185388-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-GRAB_OTmut (#185388). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OTmut plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) control sensor GRAB_OTmut in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

Oct. 21, 2024

Academic Institutions and Nonprofits only

#185388-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_OTmut (#185388). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OTmut plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) control sensor GRAB_OTmut in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only

#50942-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#50942). In addition to the viral particles, you will also receive purified pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#68719-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6f-WPRE-pA (#68719). In addition to the viral particles, you will also receive purified pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6f-WPRE-pA plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor with bicistronic mRuby2. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

June 5, 2018

Academic Institutions and Nonprofits only

#68717-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68717). In addition to the viral particles, you will also receive purified pAAV-CAG-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. CAG-driven, Cre dependent, GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

May 4, 2018

Academic Institutions and Nonprofits only

#68720-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68720). In addition to the viral particles, you will also receive purified pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. Cre-dependent GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#213947-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_GCaMP6f (#213947). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213943-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213918-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_jGCaMP8m (#213918). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_jGCaMP8m plasmid DNA. Expression of jGCaMP8m under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213939-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213859-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_GCaMP6f (#213859). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213833-AAV5

Ready-to-use AAV5 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213829-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_dTomato_nlsdTomato (#213829). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213944-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213814-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_dTomato_nlsdTomato (#213814). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only